

Annals of oncology : official journal of the
v. 24, no. 7 (July 2013)
General Collection
W1 AN617D
2013-07-26 08:43:10

OXFORD
UNIVERSITY PRESS

ISSN 0923-7534 (print)
ISSN 1569-8041 (online)

Volume 24 No. 7 July 2013

Annals of Oncology



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

www.annonc.oxfordjournals.org

www.esmo.org

040571

ANNALS OF ONCOLOGY - ENGLISH EDITION

2013 VOLUME 24 ISSUE 7

SISAC

Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2042



Scan to view this journal
on your mobile device

ESMO GOOD SCIENCE
BETTER MEDICINE

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

editorials

'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer
D. Santini, B. Vincenzi, F. Pantano, G. Schiavon & G. Tonini **1715**

Therapeutic windows and opportunity cost cast upon prostate cancers fatal shore
A. Goldkorn, A. M. Aparicio & D. I. Quinn **1717**

reviews

Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis
P. P. Singh & S. Singh **1721**

Targeted therapies and the treatment of non-clear cell renal cell carcinoma
J. Bellmunt & J. Dutcher **1730**

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
A. Milani, D. Sangiolo, F. Montemurro, M. Aglietta & G. Valabrega **1740**

The volume effect in paediatric oncology: a systematic review
R. R. G. Knops, E. C. van Dalen, R. L. Mulder, E. Leclercq, S. L. Knijnenburg, G. J. L. Kaspers, R. Pieters, H. N. Caron & L. C. M. Kremer **1749**

original articles

gastrointestinal tumors

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial
M. A. Gordon, H. M. Gundacker, J. Benedetti, J. S. Macdonald, J. C. Baranda, W. J. Levin, C. D. Blanke, W. Elatre, P. Weng, J. Y. Zhou, H. J. Lenz & M. F. Press **1754**

Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer
T. H. van Dijk, K. Tamas, J. C. Beukema, G. L. Beets, A. J. Gelderblom, K. P. de Jong, I. D. Nagtegaal, H. J. Rutten, C. J. van de Velde, T. Wiggers, G. A. Hospers & K. Havenga **1762**

FOLFOLX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
T. Brodowicz, T. E. Ciuleanu, D. Radosavljevic, E. Shacham-Shmueli, D. Vrbancic, S. Plate, Z. Mrcic-Krmpotic, M. Dank, G. Purkalne, D. Messinger & C. C. Zielinski **1769**

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
A. L. Cohn, J. Taberner, J. Maurel, E. Nowara, J. Sastre, B. Y. S. Chuah, M. V. Kopp, D. D. Sakaeva, E. P. Mitchell, S. Dubey, S. Suzuki, Y.-J. Hei, F. Galimi, I. McCaffery, Y. Pan, R. Loberg, S. Cottrell & S.-P. Choo **1777**

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients
Y. Zhao, W. J. Wang, S. Guan, H. L. Li, R. C. Xu, J. B. Wu, J. S. Liu, H. P. Li, W. Bai, Z. X. Yin, D. M. Fan, Z. L. Zhang & G. H. Han **1786**

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
B. M. Wolpin, E. M. O'Reilly, Y. J. Ko, L. S. Blaszczak, M. Rarick, C. M. Rocha-Lima, P. Ritch, E. Chan, J. Sprattin, T. Macarulla, E. McWhirter, D. Pezet, M. Lichinitser, L. Roman, A. Hartford, K. Morrison, L. Jackson, M. Vincent, L. Reyno & M. Hidalgo **1792**

urogenital tumors

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
K. L. Noonan, S. North, R. L. Bitting, A. J. Armstrong, S. L. Ellard & K. N. Chi **1802**

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot, D. Bianchini, E. Ileana, S. Sandhu, A. Patrikidou, C. Pezaro, L. Albiges, G. Attard, K. Fizazi, J. S. De Bono & C. Massard **1807**

Continued overleaf

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin, C. S. Higano, O. Hamid, S. Tejwani, A. Harzstark, J. J. Alumkal, H. I. Scher, K. Chin, P. Gagnier, M. B. McHenry & T. M. Beer **1813**

lung cancer

ROS1 fusions in Chinese patients with non-small-cell lung cancer
W. Cai, X. Li, C. Su, L. Fan, L. Zheng, K. Fei, C. Zhou, C. Manegold & G. Schmid-Bindert **1822**

breast cancer

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclo II
V. J. Harvey, K. J. Sharples, R. J. Isaacs, M. B. Jameson, G. M. Jeffery, B. R. McLaren, S. Pollard, G. A. Riley, A. B. Simpson, V. A. Hinder, J. N. Scott, M. V. Dzhelali & M. P. Findlay **1828**

Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
C. Skedgel, D. Rayson & T. Younis **1834**

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
S. M. Tolaney, J. Najita, J. Sperinde, W. Huang, W. Y. Chen, J. Savoie, M. Fornier, E. P. Winer, C. Bunnell & I. E. Krop **1841**

Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers
O. Brouckaert, A. Schoneveld, C. Truyers, E. Kellen, C. Van Ongeval, I. Vergote, P. Moerman, G. Floris, H. Wildiers, M. R. Christiaens, E. Van Limbergen & P. Neven, on behalf of MBC Leuven, Belgium **1847**

Attitudes of patients with metastatic breast cancer toward research biopsies
D. S. Seah, S. M. Scott, J. Najita, T. Openshaw, K. Krag, E. Frank, J. Sohl, Z. K. Stadler, M. Garrett, S. G. Silverman, J. Peppercorn, E. P. Winer, S. E. Come & N. U. Lin **1853**

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study
A. Guerrieri-Gonzaga, M. Lazzeroni, E. Botteri, D. Serrano, N. Rotmensz, M.-C. Varricchio, M. Cazzaniga, G. Bollani, S. Mora, C. Montefrancesco, G. Pruneri, G. Viale, M. Intra, V. Galimberti, A. Goldhirsch, V. Bagnardi, B. Bonanni & A. DeCensi **1859**

translational research

Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation
L. Weng, D. Ziliak, H. K. Im, E. R. Gamazon, S. Philips, A. T. Nguyen, Z. Desta, T. C. Skaar, the Consortium on Breast Cancer Pharmacogenomics (COBRA), D. A. Flockhart & R. S. Huang **1867**

hematologic malignancies

Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications
I. I. Raad, A. M. Chaftari, M. M. Al Shuaibi, Y. Jiang, W. Shomali, J. E. Cortes, B. Lichtiger & R. Y. Hachem **1873**

Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
T. Wåsterlid, P. N. Brown, O. Hagberg, H. Hagberg, L. M. Pedersen, F. D'Amore & M. Jerkeman **1879**

quality of life and supportive care

Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia
H. Ludwig, E. Müldür, G. Endler & W. Hübl **1886**

Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial
G. A. Goossens, M. Jérôme, C. Janssens, W. E. Peetermans, S. Fieuws, P. Moons, J. Verschakelen, K. Peerlinck, M. Jacquemin & M. Stas **1892**

phase I and pharmacokinetics

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
R. K. Kelley, H. S. Nimeiri, P. N. Munster, M. T. Vergo, Y. Huang, C.-M. Li, J. Hwang, M. F. Mulcahy, B. M. Yeh, P. Kuhn, M. S. Luttgen, J. A. Grabowsky, L. Stucky-Marshall, W. M. Korn, A. H. Ko, E. K. Bergsland, A. B. Benson III & A. P. Venook **1900**

epidemiology

Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
A. Larghi, N. Panic, G. Capurso, E. Leoncini, D. Arzani, R. Salvia, M. Del Chiaro, L. Frulloni, P. G. Arcidiacono, A. Zerbi, R. Manta, C. Fabbri, M. Ventrucci, I. Tarantino, M. Piciocchi, A. Carnuccio, U. Boggi, G. Costamagna, G. Delle Fave, R. Pezzilli, C. Bassi, M. Bulajic, W. Ricciardi & S. Boccia **1907**

Continued overleaf

Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study
A. Discacciati, N. Orsini, S.-O. Andersson, O. Andr n, J.-E. Johansson, C. S. Mantzoros & A. Wolk **1912**

Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a meta-analysis
Q. J. Wu, L. Xie, W. Zheng, E. Vogtmann, H. L. Li, G. Yang, B. T. Ji, Y. T. Gao, X. O. Shu & Y. B. Xiang **1918**

sarcomas

Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival
D. Garbay, R. G. Maki, J. Y. Blay, N. Isambert, S. Piperno Neumann, C. Blay, E. Zanardi, P. Boudou-Rouquette, L. Bozec, F. Duffaud, F. Bertucci & A. Italiano **1924**

Phase II study on lapatinib in advanced EGFR-positive chordoma
S. Stacchiotti, E. Tamborini, S. Lo Vullo, F. Bozzi, A. Messina, C. Morosi, A. Casale, F. Crippa, E. Conca, T. Negri, E. Palassini, A. Marrari, E. Palmerini, L. Mariani, A. Gronchi, S. Pilotti & P.G. Casali **1931**

clinical trials

Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents
R. Jamal, R. A. Goodwin, D. Tu, W. Walsh, D. Lacombe & E. A. Eisenhauer **1936**

Non-inferiority cancer clinical trials: scope and purposes underlying their design
R. P. Riechelmann, A. Alex, L. Cruz, G. M. Bariani & P. M. Hoff **1942**

letters to the editor

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?
F. Buchegger, J.-P. Mach, O. W. Press, A. Bischof Delaloye, S. M. Larson, J. O. Prior & N. Ketterer **1948**

Spin and bias: the tip of the iceberg
V. W. Berger **1949**

Spin and bias: the tip of the iceberg
F. E. Vera-Badillo & I. F. Tannock **1949**

subscriptions

A subscription to *Annals of Oncology* comprises 12 issues plus supplements in each volume. Prices include postage, and for subscribers outside the UK delivery is by Standard Air.

Annual Subscription Rate (Volume 24, 12 issues, 2013)

Institutional – Academic / Non profit only
Print and Online £1319.00/\$2639.00/€1980.00
Online Only £1044.00/\$2089.00/€1568.00
Print Only £1209.00/\$2419.00/€1815.00

Institutional – Corporate
Print and Online £1649.00/\$3299.00/€2475.00
Online Only £1305.00/\$2611.00/€1959.00
Print Only £1511.00/\$3024.00/€2269.00

Personal
Print and Online £1144.00/\$2288.00/€1717.00
Please note: US\$ rate applies to US & Canada, Euros applies to Europe, UK£ applies to UK and Rest of World.

There may be other subscription rates available, for a complete listing please visit www.annonc.oxfordjournals.org/subscriptions

Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company at <http://www.periodicals.com/oxford.html> or Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com. Tel: (518) 537-4700. Fax: (518) 537-5899

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: jnls.cust.serv@oup.com. Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: +44 (0)1865 353485. **In the US, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: jnlorders@oup.com. Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. **In Japan, please contact:** Journals Customer Service, Oxford University Press, 4-5-10-8F Shiba, Minato-ku, Tokyo 108-8386, Japan. Tel. +81 3 5444 5858. Fax. +81 3 3454 2929. E-mail: custserv.jp@oup.com

DOI: For information about DOIs and to resolve them, please visit <http://www.doi.org>

Methods of payment. (i) Cheque (payable to Oxford University Press, to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford OX2 6DP, UK) in GB£ Sterling (drawn on a UK bank), US\$ Dollars (drawn on a US bank), or EU€ Euros. (ii) Bank transfer to Barclays Bank Plc, Oxford

Group Office, Oxford (bank sort code 20-65-18) (UK), overseas only Swift code BARC GB 22 (GB£ Sterling to account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars to account no. 66014600, IBAN GB27BARC20651866014600; EU€ Euros to account no. 78923655, IBAN GB16BARC20651878923655). (iii) Credit card (Mastercard, Visa, Switch or American Express).

Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford University Press, Oxford, UK. The US annual print subscription or price is \$2513.00. Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11431.

Subscription records are maintained at Oxford University Press, Oxford, UK.

supplements, reprints and corporate sales

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email: special.sales@oup.com, fax: +44 (0) 1865 353774 or visit www.oxfordjournals.org/sales.

permissions

For information on how to request permissions to reproduce articles/information from this journal, please visit www.oxfordjournals.org/permissions.

advertising

Advertising, inserts and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax +44 (0)1865 353774; E-mail: jnlsadvertising@oup.com

environmental and ethical policies

Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on environmental and ethical policies.

drug disclaimer

All reasonable precautions have been taken by the authors, editors and publisher to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publisher. The ultimate responsibility for the use and dosage of drugs mentioned in *Annals of Oncology* and in the interpretation of published material lies with the medical practitioner. The editors and publisher can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

© The European Society for Medical Oncology 2013

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

Typeset by Techset Composition Ltd, Salisbury, UK.
Printed by Bell and Bain Ltd., Glasgow, UK.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.